Since April 2022, the Dry Eye Foundation has been voicing concerns over the packaging of preservative-free drops as well as availability of noncompliant drops at online retailers.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

Groundbreaking treatment for patients with bullous keratopathy approved in Japan.

The annual conference will take place September 6-9 at the Renaissance Schaumburg Convention Center in Schaumburg, IL.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

Surgical interventions once disease progresses.

Provide better, more cohesive patient care with comanagement.

The goal of the inaugural International Keratoconus Academy (IKA) Keratoconus Symposium in Scottsdale, Arizona, was to help preserve vision.

Catch up on what happened in optometry during the week of May 22-May 26.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

As part of the American Diabetes Association's Health Equity Now program, the organization has partnered with Genentech, piloting a partnership within Alabama to specifically focusing on tackling barriers related to diabetic eye disease.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

Artificial intelligence is the future of optometric disease monitoring.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Growing evidence supports dual therapy to slow progression.

An epidemiologic study of myopia in a Chinese province found that economic status, gender, and age were associated with rates of myopia.

Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.

This single-ingredient tear stabilizer from Bausch + Lomb and Novaliq could become the choice therapeutic for dry eye disease.